Making A Difference

Our 2022 Sustainability Report details how we seek to create value for and together with our key stakeholders – the people who trust our medicines every day, the health systems who rely on us, the people that make up Viatris, our partners and the investors who believe in our ability to execute on our ambitious mission. Our business and operating model is deliberately designed and implemented to deliver on our strategy to build and sustain access to medicine at scale. Viatris is proud to have served approximately 1 billion patients in 2022.

Read the report
2022 Sustainability Fact Sheet
A Letter from our CEO, Scott A. Smith

Viatris Joins USA Today’s inaugural list of America’s Climate Leaders 2023

At Viatris, we recognize the importance of environmental action and are proud of our work to reduce the effects of climate change to help improve the health of the patients we serve. This commitment to reduce emission intensity named Viatris on USA Today’s inaugural list of America’s Climate Leaders 2023. This recognition is a testament to the company’s success in increasing renewable energy use, enhancing operational efficiencies, and transitioning to upgraded equipment and alternative fuels.

  • Viatris commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030 and to reduce absolute Scope 3 GHG emissions by 25%.
  • The Science Based Target Initiative (SBTi) independently assessed and approved our greenhouse gas emissions targets in line with its strict, globally recognized criteria in 2022. Our targets allow us to reduce greenhouse gas emissions in line with the Paris Agreement goal of limiting global warming to 1.5°C preindustrial levels.

Viatris Corporate Social Responsibility in the U.S. - Highlights

At Viatris, we know our work has the potential to positively impact the health of communities worldwide, including in the U.S. Whether through philanthropic giving, partnerships or volunteerism, our efforts support access to education and healthcare as well as local community programs.

Fighting infectious disease

Our commitment to combatting infectious disease is significant. Today, more than 40 percent of the world’s HIV/AIDS patients use one of our products and more than 60 percent of the world’s HIV+ children use one of our treatments. In the U.S., we have launched lower-cost options to several common treatments in an effort to reduce the high cost of care. And recently, we partnered with the TB Alliance to develop a treatment for multi-drug-resistant tuberculosis.

tbAlliance_logo

Sesame Workshop

Viatris has partnered with Sesame Workshop, the nonprofit organization behind Sesame Street, to develop resources that support the social and emotional needs of families during the COVID pandemic. These resources, available in multiple languages, include Grover and his mom making Grandma’s soup over video chat when they can’t be together and Elmo’s dad helping him name and cope with the feelings of fear of getting sick.

sesame_logo

Dispensary of Hope

Since 2012, Viatris has partnered with Dispensary of Hope, an organization that connects medication surplus from manufacturers and physicians with low-income and underinsured patients in the U.S. We have donated more than 230 million doses spanning a variety of therapeutic areas.

hope_logo

Impacting the Next Generation

We have partnered with West Virginia University to develop STEMCARE, a program that instills a growth mindset in children and youth through personal application of problem-solving skills developed from science, technology, engineering, and math.
300+
Children participating in Classrooms around West Virginia
500+
Participation in STEMCARE Programming through 4-H Camps

Learn More

Corporate responsibility

Viatris works to advance responsible and sustainable operations and leverage our collective expertise to empower people to live healthier at every stage of life. Visit our corporate site to learn more.
Learn more